US Bancorp
SLS icon

US Bancorp’s SELLAS Life Sciences SLS Stock Holding History

US Bancorp’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.8K Buy
+1,285
New +$16.1K ﹤0.01% 3329

Other funds holding SLS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
DI
DAGCO Inc Westlake, Ohio $576M AUM 21.79% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Opus Capital Group
Opus Capital Group Cincinnati, Ohio $1.02B AUM 13.75% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

US Bancorp's SLS Position: Q3 2026 in Review

US Bancorp opened a new position in SELLAS Life Sciences (SLS) in Q3 2026: 1,285 shares worth $15.8K. The stake represents ﹤0.01% of the portfolio and ranks #3329 among its holdings.

112 funds tracked by Wall St. Rank hold SLS as of Q3 2026.

  • US Bancorp held 1,285 shares of SELLAS Life Sciences worth $15.8K as of Q3 2026.
  • SELLAS Life Sciences was a new US Bancorp position in Q3 2026.
  • SELLAS Life Sciences made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #3329 holding.
  • 112 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.